Neurocrine Biosciences (FRA:NB3) Marketable Securities : €749 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Neurocrine Biosciences's Marketable Securities for the quarter that ended in Mar. 2024 was €749 Mil.

Neurocrine Biosciences's annual Marketable Securities increased from Dec. 2021 (€328 Mil) to Dec. 2022 (€686 Mil) and increased from Dec. 2022 (€686 Mil) to Dec. 2023 (€716 Mil).

Neurocrine Biosciences Marketable Securities Historical Data

The historical data trend for Neurocrine Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Marketable Securities Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

502.38

504.63

327.89

685.72

715.72

Neurocrine Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															738.61	753.63	750.91	715.72	749.16

Neurocrine Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Neurocrine Biosciences (FRA:NB3) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Neurocrine Biosciences Marketable Securities Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (FRA:NB3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

NBIX:USA N1BI34:Brazil

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (FRA:NB3) Headlines

No Headlines